CRBU FY2029 EPS Reduced by Brookline Capital Management

Key Points

• Brookline Capital Management has reduced Caribou Biosciences' FY2029 earnings per share (EPS) estimate from $16.99 to $16.89.
• Caribou Biosciences reported an EPS of ($0.35) for the recent quarter, beating expectations of ($0.40), with revenue of $2.67 million exceeding forecasts.
• HC Wainwright has downgraded its price target on Caribou Biosciences’ shares from $9.00 to $3.00, indicating a significant reassessment of the company's stock value.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities research analysts at Brookline Capital Management cut their FY2029 earnings per share (EPS) estimates for Caribou Biosciences in a report released on Tuesday, August 12th. Brookline Capital Management analyst L. Cann now forecasts that the company will earn $16.89 per share for the year, down from their prior forecast of $16.99. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The business had revenue of $2.67 million for the quarter, compared to analysts' expectations of $1.64 million. Caribou Biosciences had a negative return on equity of 57.10% and a negative net margin of 1,800.93%.

Several other analysts have also issued reports on CRBU. HC Wainwright restated a "buy" rating and set a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Wall Street Zen upgraded shares of Caribou Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th.

Caribou Biosciences Price Performance

NASDAQ CRBU traded down $0.11 during trading on Thursday, hitting $1.85. 333,218 shares of the company's stock traded hands, compared to its average volume of 1,346,454. The stock has a fifty day moving average of $1.64 and a two-hundred day moving average of $1.24. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.00. The firm has a market cap of $171.59 million, a P/E ratio of -1.05 and a beta of 2.55.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently modified their holdings of CRBU. JPMorgan Chase & Co. boosted its holdings in shares of Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after purchasing an additional 2,062,563 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Caribou Biosciences by 112.8% during the fourth quarter. Wells Fargo & Company MN now owns 91,988 shares of the company's stock worth $146,000 after purchasing an additional 48,759 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Caribou Biosciences by 43.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock worth $74,000 after purchasing an additional 14,021 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after purchasing an additional 21,416 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Caribou Biosciences by 12.0% during the fourth quarter. Barclays PLC now owns 145,417 shares of the company's stock worth $231,000 after purchasing an additional 15,578 shares during the period. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.